Evaluation of pharmacokinetic (PK) drug-drug interactions (DDI) between trebananib (AMG 386) and paclitaxel (PTX) in patients (pts) with advanced solid tumors.
Jennifer Robinson Diamond
Research Funding - Amgen
Neeraj Agarwal
Consultant or Advisory Role - Exelixis (U); Medivation (U)
Honoraria - Dendreon
Research Funding - Amgen; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; ImClone Systems; Medivation; Novartis; Pfizer; Takeda
Daniel W. Bowles
No relevant relationships to disclose
Elaine Tat Lam
Consultant or Advisory Role - Exelixis
Research Funding - Astellas Pharma; Bayer; Exelixis; Janssen Pharmaceutical
Theresa Louise Werner
Research Funding - Amgen
Benjamin Wu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Erik Rasmussen
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Erick Gamelin
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Felipe Soto
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Gregory R. Friberg
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Yu-Nien Sun
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Sunil Sharma
Research Funding - Amgen